CANF: Gunggung dhuwit awis saben saham canfite.com

Lambang korporat lan logo Can-Fite BioPharma (CANF)

The cash per share history demonstrates the liquid basis of Can-Fite BioPharma (CANF), where the 2.23 metric serves as the target level. The issuer integrates ESG standards into its oncology research, reducing harmful emissions and monitoring ethics. Revenues rely on adenosine receptors for the treatment of cancer and psoriasis, although current inflows are limited to Asian licensing advances during the late-stage clinical trial period.

CANF: Dhuwit awis saben saham Can-Fite BioPharma Ltd 04.07.2022 - 20.11.2026

Rincian analitis perusahaan Can-Fite BioPharma

- rega pasar lan target rega analis:
- rincian posisi dhuwit lan arus kas:
Ringkesan analisis perusahaan:CANF, Can-Fite
Produk asli canfite.com

Professional selection of resilient assets is based on liquidity analysis to assess expansion potential. This metric determines the amount of available cash per common share. The trend in cash per share reflects the rate of capital expenditure on operational needs. For Can-Fite BioPharma (CANF), this is critical when funding research and development in oncology and hepatology. The presence of reserves confirms the company's ability to penetrate high-yield medical markets.